Skip to main content

Table 2 Adherence in men receiving FDC and concomitant therapy with an α-blocker plus an antimuscarinic

From: A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

  FDC
α-blocker and antimuscarinic
Concomitant therapy
α-blocker antimuscarinic
MPR-fixed
N 566 726 726
 Mean (SD) 0.91 (0.52) 0.95 (0.37) 0.89 (0.31)
 Adherent,a n (%) 453 (80.0) 623 (85.8) 546 (75.2)
MPR-variable
N 566 726 726
 Mean (SD) 0.67 (0.31) 0.69 (0.34) 0.64 (0.32)
 Adherent,a n (%) 275 (48.6) 358 (49.3) 319 (43.9)
MPR-fixed (persistent men only)
N 313 380 380
 Mean (SD) 0.83 (0.21) 0.93 (0.22) 0.85 (0.22)
 Adherent,a n (%) 235 (75.1) 324 (85.3) 282 (74.2)
  1. FDC fixed-dose combination, MPR medical possession ratio, SD standard deviation
  2. aMPR of ≥80%